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Abstract
Background: Whereas demyelination underlies early neurological symptoms in multiple sclerosis (MS), axonal damage
is considered critical for permanent chronic deficits. Intracerebral infection of susceptible mouse strains with Theiler’s
murine encephalomyelitis virus (TMEV) results in chronic induced demyelinating disease (TMEV-IDD) with progressive
axonal loss and neurologic dysfunction similar to progressive forms of MS. We previously reported that treatment of
chronic TMEV-IDD mice with a neurite outgrowth-promoting natural human antibody, HIgM12, improved brainstem
NAA concentrations and preserved functional motor activity. In order to translate this antibody toward clinical trial, we
generated a fully human recombinant form of HIgM12, rHIgM12, determined the optimal in vivo dose for functional
improvement in TMEV-IDD, and evaluated the functional preservation of descending spinal cord axons by retrograde
labeling.
Findings: SJL/J mice at 45 to 90 days post infection (dpi) were studied. A single intraperitoneal dose of 0.25 mg/kg of
rHIgM12 per mouse is sufficient to preserve motor function in TMEV-IDD. The optimal dose was 10 mg/kg. rHIgM12
treatment protected the functional transport in spinal cord axons and led to 40 % more Fluoro-Gold-labeled brainstem
neurons in retrograde transport studies. This suggests that axons are not only present but also functionally competent.
rHIgM12-treated mice also contained more mid-thoracic (T6) spinal cord axons than controls.
Conclusions: This study confirms that a fully human recombinant neurite outgrowth-promoting monoclonal
IgM is therapeutic in a model of progressive MS using multiple reparative readouts. The minimum effective
dose is similar to that of a remyelination-promoting monoclonal human IgM discovered by our group that is
presently in clinical trials for MS.




Multiple sclerosis (MS) is an inflammatory demyelinating
disease of the central nervous system (CNS). Axonal dam-
age is considered critical for permanent chronic deficits in
progressive MS, but the precise mechanisms by which
axonal injury occurs in MS are unclear. None of the cur-
rently FDA-approved drugs or candidates in clinical trial
protect neurons and axons from degeneration. Theiler’s
murine encephalomyelitis virus (TMEV) is a single-
stranded RNA virus that belongs to the Picornaviridae
family. Intracerebral injection of TMEV induces an in-
flammatory demyelinating disease in the spinal cord of
susceptible strains of mice following infection [1]. TMEV-
induced demyelinating disease (TMEV-IDD) is a natural
chronic progressive CNS demyelinating disease of suscep-
tible strains of mice, with similarities to primary progres-
sive MS [2]. The TMEV-induced model of demyelinating
disease is a reasonable platform for therapeutic drug dis-
covery for progressive forms of demyelination.
We previously reported that a human IgM monoclonal
antibody, HIgM12, bound to the surface of neurons,
supported robust neurite extension when presented as a
substrate, and overrode the neurite extension inhibition
of CNS myelin and myelin-associated glycoprotein
(MAG) [3–5]. We also showed that a single 10 mg/kg
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dose of HIgM12, when peripherally administered, im-
proved clinical disease course of chronic virus-infected
mice beginning 2 weeks following treatment, which per-
sisted for 8 weeks [6]. In a recent follow-up study,
HIgM12, when administered intraperitoneally to 90-day
TMEV-IDD mice, improved brainstem NAA concentra-
tions, a surrogate biomarker for the density of spinal
cord axons, at 5 and 10 weeks following treatment [7].
This improvement was present even though HIgM12
does not promote spinal cord remyelination. A reagent
that protects axons without associated remyelination
would be a critical drug by itself or paired with immune-
modulatory or remyelination-promoting therapies. To
translate this IgM to clinical trial, we generated a fully
human recombinant form of the IgM (rHIgM12) from
CHO cells and tested this for efficacy in the TMEV
model. We first determined the minimum and optimum
dose of rHIgM12 that improves neurologic function in
vivo by locomotor monitoring of TMEV-IDD mice.
Active axonal retrograde labeling relies on both ana-
tomically continuous axons and preserved retrograde
transport mechanism which provides an assessment of
axonal integrity. Retrograde labeling analysis of spinal
cord axons in chronically demyelinated mice previously
revealed a marked reduction in the number of labeled
neuronal cell bodies in the brainstem [8]. Our recent re-
port [7] describing an increase in brainstem NAA con-
centrations after treatment with HIgM12 led us to
determine whether treatment with rHIgM12 results in
an increased number of retrograde tracer-positive




The Mayo Clinic Institutional Animal Care and Use
Committee (IACUC) approved all animal protocols used
in this study.
Theiler’s virus model of demyelination
Demyelinating disease was induced in 8-week-old SJL/J
mice by intracerebral injection of 10 μl containing 2.0 × 105
plaque-forming units (PFUs) of Daniel’s strain TMEV [9].
This typically results in >98 % incidence of infection with
rare fatalities.
Antibodies
Human IgM12 was identified and isolated from a patient
(N°12) with Waldenstrom’s macroglobulinemia carrying
high levels of this monoclonal protein for years without
detriment. The variable region amino acid and nucleotide
sequences for the heavy and light chains are available in
GenBank under the accession numbers DQ146928 and
DQ146929, respectively. rHIgM12 was expressed in CHO-
S cells (GibcoBRL, cat# 11619). Plasmids expressing the
heavy and light chain coding sequences were co-
transfected along with a human J chain. The resulting cells
were selected with increasing doses of methotrexate, and
clones that produced IgM as measured by ELISA were
sub-cloned and expanded. A stable clone was expanded,
banked, and successfully grown in hollow fiber or wave
bags to obtain supernatant. rHIgM12 was purified in a
qualified GLP facility. Briefly, diafiltered culture super-
natant containing rHIgM12 was subjected to a three-step
purification protocol (Fig. 1a). First, culture supernatant
was loaded on a CHT Ceramic Hydroxyapatite, Type II
(Bio-Rad) column and eluted using 250 mM sodium phos-
phate (NaOH, pH 7.0). The eluted solution was then
passed through a CIM QA-8f Monolithic column (BIA
Separations) followed by elution with 250 mM NaOH,
500 mM NaCl (pH 7.0). In the final step of purification,
the eluate from the second step was further subjected to
separation on a Sephacryl S-300 HR column in the pres-
ence of 50 mM Na2HPO4, 150 mM NaCl (pH 7.0). Collec-
tion of only peak fractions at the final step allowed
approximately 6-fold concentration of the eluate from the
monolith column. The purity of eluates at each step is
shown (Fig. 1b, c). The stock rHIgM12 preparation was
stored as 5 mg/ml aliquots. The final IgM was validated
using titrated potency assays of binding to the surface of
neurons and support of neurite extension. The potency of
rHIgM12 and the serum-derived IgM were compared [10]
and found to be identical therapeutically. rHIgM12 can be
obtained for non-commercial experimental use by contact-
ing the corresponding author. The control human IgM
used was isolated from human serum [4]. It did not bind
to neurons in culture or live tissue slices nor support neur-
ite extension in cell culture. Informed consent was ob-
tained from all patients for the use of serum samples for
research purposes.
Treatment of mice
Dosing study: SJL mice at 45 days post infection (dpi), the
time point when demyelination in the spinal cord is well
established and before substantial axon loss, were treated
with a single intraperitoneal dose of rHIgM12 (0.25, 2.5,
10, or 25 mg/kg) or isotype control IgM (10 mg/kg). Dos-
ing was based on the average weight of an adult SJL
mouse (20 g). Retrograde labeling study: SJL mice at 90
dpi, the time point when axonal degeneration is present
and progressing, were treated with a single intraperitoneal
dose of rHIgM12 (10 mg/kg) or saline.
Spontaneous activity monitoring
Spontaneous horizontal and vertical locomotor activity
was recorded using open-field (OF) locomotor activity
monitors (Omnitech Electronics; Columbus, OH) and
Fusion v5.0 software. Each monitor consists of sets of 16
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light beam arrays in the horizontal x and y axes. The
hardware detects beams broken by animal movements
to determine the location within the cage. In all cages,
mice were exposed to identical environmental condi-
tions: (a) freely accessible food and water; (b) a normal
12-h light/dark cycle; and (c) 70 °F ambient temperature.
Five SJL mice at 45 dpi were placed in each cage, and
baseline spontaneous activity was collected over a period
of 5 consecutive days. Groups of mice were then treated
with a single dose of rHIgM12 (0.25, 2.5, 10, or 25 mg/kg)
or with 10 mg/kg of control human IgM antibody. Follow-
ing treatment, mice were continuously monitored for
56 days. The total horizontal and vertical activity data,
quantified as mean hourly mean breaks, was exported to
an Excel (Microsoft Corporation) compatible file for fur-
ther analysis. The original activity box data sets were first
normalized to baseline activity independently for each
group of mice (Fig. 2a, b) followed by a polynomial
curve fitting (Fig. 2c, d). We described this method-
ology in greater detail (see [6]). Briefly, the model
was designed to allow for polynomial terms up to any
degree (xn) and estimated shape parameters separately
for each dose and treatment group. For the analysis
of datasets in this study, we chose the third-degree
polynomial followed by normalization of curves to y-
axis = 0. This allowed us sufficient flexibility to model
non-linear effects over time. Polynomial analysis of data
sets was considered ideal as it allowed us to perform direct
pairwise comparison at regular intervals across the entire
time frame to determine when treatment groups have sig-
nificantly diverged. In addition, a polynomial fit clarifies
data by eliminating noise to draw visual attention on the
general trend over the entire time frame. Polynomial
regression models were performed and plotted using
Graphpad Prism v5.0.
Retrograde labeling
Retrograde labeling [8] of brainstem neurons was
performed on 23 mice (uninfected = 3, rHIgM12 = 9,
saline = 11) at 9 weeks after antibody treatment. Briefly,
dorsal laminectomy of the lower thoracic vertebrae was
performed on anesthetized mice. The spinal cord was
hemisected on the right side using microdissecting
blades. The retrograde tracer, Fluoro-Gold, was applied
and the surgery site was closed. One week post-surgery
(i.e., 10 weeks post-treatment), mice were terminally
anesthetized, perfused with 4 % paraformaldehyde, and
brains and spinal cords were collected. Serial vibratome
(Lancer Series 1200) sections (40 μm thick) of the brain-
stem were collected and mounted under Vectashield
(Vector Laboratories Inc., Burlingame, CA). Cell bodies
containing retrograde tracer (Fluoro-Gold), visualized by
UV illumination (360–370-nm excitation, 420–460-nm
emission) were counted at 200× from 16 brainstem
slices per mouse. A cell was counted as positive if a large
cross-section of the cell body was labeled with Fluoro-
Gold. All analyses were performed without knowledge of
the experimental groups.
Spinal cord morphometry
We assessed spinal cord morphometry in all groups
10 weeks following treatment. Mice were anesthetized with
sodium pentobarbital and perfused intracardially with
Trump’s fixative (phosphate-buffered 4 % formaldehyde/
Fig. 1 Purification of rHIgM12 to >97 %. IgM was isolated from culture supernatant using a three-step purification protocol. a shows a flow diagram of
the three-step purification protocol. b shows the final eluate from the third step, i.e., separation on a Sephacryl S-300 HR column in the presence of
10 mM NaOH and 150 mM NaCl (pH 7.0). c shows an SDS-PAGE gel of the following: lane 1—molecular weight markers, lanes 2 and 3—20-μl samples
of the peak fraction showed in b. The IgM heavy chain (H, 75 kDa) and light chain (L, 25 kDa) are shown
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1 % glutaraldehyde, pH 7.4). Spinal cords were removed
and sectioned precisely into 1-mm blocks. In order to rep-
resent samples along the length of the spinal cord, every
third block was postfixed, stained with osmium tetroxide,
and embedded in araldite plastic (Polysciences, Warrington,
PA). One-micrometer sections were cut and stained with
4 % p-phenylenediamine to visualize the myelin sheaths.
We examined ten spinal cord cross-sections, spanning the
entire spinal cord from cervical to the distal lumbar
regions, from each mouse. Each spinal cord quadrant from
every coronal section was graded for the presence of in-
flammation and demyelination. Quadrants with inflamma-
tion were defined by the presence of inflammatory cells
lining the meninges. Areas of demyelination were defined
as containing naked axons, macrophage infiltration, myelin
ovoids, and degenerated axon profiles. These areas were
well demarcated and allow accurate quantitative assessment
at 10× and 40× magnifications, respectively. Demyelination
Fig. 2 rHIgM12 treatment improves both horizontal and vertical activity in SJL mice during established demyelinating disease. Groups of SJL mice
(N = 10 per treatment group) at 45 dpi were placed in activity monitoring boxes. Baseline measurements were collected over 8 days. Beginning at
treatment (time zero), mice were monitored continuously over an additional 8 weeks. a, c correspond to horizontal activity and b, d correspond to vertical
activity. a, b Original, unfiltered recordings for horizontal and vertical activity normalized to baseline; c, d third-order polynomial fitting of standardized z
values normalized to baseline revealed improvement in both horizontal and vertical activity of the rHIgM12-treated group compared to the control IgM-
treated group. Horizontal (e) and vertical (f) nocturnal activity of rHIgM12-treated mice compared to control IgM-treated mice significantly diverged
above the x-axis (more activity) (p < 0.05) post-treatment. The pointwise lower 95 % confidence bands for the nocturnal activity are represented on the
y-axis scale
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or inflammation scores were expressed as the percentage of
spinal cord quadrants examined with pathological abnor-
mality. A maximum score of 100 indicated pathological ab-
normality in every quadrant of all spinal cord sections of a
given mouse. All grading was performed on coded sections
without knowledge of the experimental group.
To quantify myelinated axons, a mid-thoracic (T6)
spinal cord section from each animal was examined.
This level of the cord was chosen because it contains
both ascending axons and descending axons some of
which have neuronal bodies in the brainstem [11]. To
ensure a uniform intensity of myelin labeling, all spinal
cord T6 sections used in the study were stained with the
same batch of 4 % para-phenylenediamine for exactly
20 min. An Olympus Provis AX70 microscope and a
60× oil-immersion objective were used to capture six
sample areas of normal-appearing white matter without
demyelination from each section. The fields were col-
lected in a clockwise manner around the section to ob-
tain representative samplings of the posterior-lateral,
antero-lateral, and anterior columns. Images were cen-
tered between the gray matter and meningeal surface.
Approximately 400,000 μm2 of white matter was sam-
pled from each mouse. Absolute myelinated axon num-
bers were measured using automated counting software
that recognizes circular intact myelin sheathes and cal-
culated as reported [12]. Data were represented as the
absolute number of all axons sampled per mid-thoracic
spinal cord section. All values were averaged per group.
Statistics
Data from activity monitoring: Statistical comparisons of
treatment groups were performed using the predicted
model values and respective standard errors based on
the z-statistic (SAS Institute, Inc.). Direct pairwise com-
parisons of treatments were performed for each day
across the entire time frame, and statistical significance
was determined at the typical a = 0.05 threshold. No ad-
justments were made for multiple comparisons. Data for
retrograde labeling and axon-count analysis were com-
pared by Student’s t test if normally distributed or by
Mann-Whitney rank sum test if non-normally distrib-
uted. In all analyses, p < 0.05 was considered as statisti-
cally significant. Correlation coefficients between paired
sets of data were determined using the Pearson product
moment correlation.
Results
Nocturnal behavior is a sensitive measure of neurologic
deficits in TMEV-IDD [6]. In this study, we used this assay
to determine the minimum and the most effective dose of
rHIgM12 that improves spontaneous horizontal and verti-
cal locomotor activity in TMEV-IDD. To address this, we
monitored 45 dpi TMEV-IDD mice (N = 10 two groups of
5 mice per treatment) treated with either rHIgM12 at 0.25,
2.5, 10, or 25 mg/kg or control human IgM (10 mg/kg).
Following treatment, spontaneous activity was recorded
continuously over 8 weeks. The original raw activity data is
noisy (Fig. 2a, b). In order to allow a better visual compari-
son, we subjected the data to third-degree polynomial curve
fitting of standardized z values (Fig. 2c, d). This allowed a
visual comparison of groups. Using direct pairwise compari-
sons (Fig. 2e, f) of activity after polynomial fitting, we deter-
mined that improved horizontal nocturnal motor function
in rHIgM12-treated mice became statistically significant at
days 6, 9, 3, and 14 post-treatment for the 0.25-, 2.5-, 10-,
and 25-mg/kg doses, respectively, as compared to control
IgM (Fig. 2e). Improvement in horizontal nocturnal activity
of rHIgM12-treated animals persisted until the end of ex-
periment at 8 weeks. Improved vertical nocturnal motor
function in rHIgM12-treated mice became statistically sig-
nificant at days 12, 15, and 23 post-treatment for the 2.5-,
10-, and 25-mg/kg doses, respectively, as compared to con-
trol IgM (Fig. 2f). Vertical activity in the 0.25-mg/kg dose
group was not statistically significant at any time point
post-treatment when compared to control IgM.
We recently reported that treatment of TMEV-
infected SJL mice with the myelin/oligodendrocyte-re-
active human IgM, rHIgM22, resulted in more retro-
gradely labeled neuronal cell bodies in the brainstem
indicating that improving the level of remyelination can
preserve function in spinal cord axons [13]. We used the
same retrograde labeling assay to investigate whether
treatment with rHIgM12, which does not improve the
levels of remyelination, could directly protect neurons in
the brain stem and spinal cord axons. Functional preser-
vation of spinal cord axons may underlie rHIgM12 im-
provement of brainstem NAA concentrations [7] and
locomotor activity. Retrograde labeling relies on both
anatomically continuous axons and preserved retrograde
transport mechanisms. We established TMEV-IDD in 20
susceptible SJL mice. Nine mice were treated at 90 dpi
with 10 mg/kg of rHIgM12; the remaining 11 mice were
administered through vehicle. At 9 weeks post-
treatment, we performed retrograde labeling on all 23
mice (uninfected = 3, rHIgM12 = 9, saline = 11). Figure 3a
shows an example of a cluster of fluorescently labeled
neurons in the brainstem, where cell bodies as well as
dendrites and axons are clearly seen. For each descending
neuron population, cell bodies containing retrogradely
transported Fluoro-Gold label were quantified. Uninfected
mice (N = 3) had an average number of 2983 ± 39 (mean ±
SEM) labeled brainstem neurons. Retrograde labeling stud-
ies performed in demyelinated mice demonstrated a large
reduction in fluorescently labeled neuron cell bodies in the
brainstem [8]. When we quantified fluorescently labeled
brainstem neurons in TMEV-IDD mice, as expected, we
found fewer labeled neurons compared to uninfected mice.
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We counted on average 1185 ± 98 labeled neurons in the
control-treated animals (N = 11) and 1682 ± 134 labeled
neurons in rHIgM12-treated animals (N = 9). The differ-
ence in labeled neuron numbers between the rHIgM12-
treated group compared to the saline-treated group was
significantly different (p = 0.009, Mann-Whitney test, two-
tailed) (Fig. 3b).
We investigated the spinal cord pathology at 10 weeks
post-treatment. Ten plastic-embedded cross-sections
encompassing the entire length of the cord from each
mouse were scored for demyelination (Fig. 3c) and in-
flammation (Fig. 3d). Pathological scores were similar
between both groups of mice. We then determined the
number of intact axons present in mid-thoracic (T6)
spinal cord sections. Six areas encompassing approxi-
mately 400,000 μm2 of white matter were systematically
sampled from each mouse, and the total number of mid-
thoracic axons was compared across treatment groups
(Fig. 3e). We found more axons in the rHIgM12-treated
group compared to the saline-treated group (15,782 ±
736 vs 13,758 ± 575, p = 0.038). When the quantity of
retrogradely labeled brainstem neurons was plotted as a
function of the number of intact myelinated axons at the
T6 level from all animals, irrespective of the treatment
Fig. 3 rHIgM12 treatment improves the number of retrograde-labeled brainstem neurons and preserves spinal cord axons, but does not affect
spinal cord demyelination. a Fluoro-Gold-labeled neurons were counted in brain stem sections. The panel shows an example of a cluster of fluo-
rescently labeled neurons in the brainstem. Extensive labeling of cell bodies as well as axons and dendrites can be easily appreciated. b rHIgM12
treatment increased the number of retrograde-labeled brainstem neurons compared to the saline-treated group (p = 0.009, Mann-Whitney rank
sum test). The number of labeled neurons in uninfected positive control mice (N = 3, circles) is shown for reference. Forest plots show the average
number of retrograde-labeled brainstem neurons ± SEM per treatment group: rHIgM12 (red triangles) and saline (blue boxes). Mice from both treatment
groups had similar levels of spinal cord c demyelination and d inflammation pathology. Pathology analysis was performed blinded. eWhen the number of
myelinated mid-thoracic-level spinal cord axons was compared between treatment groups, rHIgM12-treated mice contained 14.7 % more axons than the
saline-treated group (p= 0.038, Mann-Whitney rank sum test). f The number of fluorescent retrograde-labeled brain stem neurons in each mouse correlated
positively and significantly with the number of thoracic-level myelinated spinal cord axons (p= 0.016, R2 = 0.28)
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groups (Fig. 3f ), we found a positive and significant cor-
relation (R2 = 0.28; p = 0.016).
Discussion
There is much evidence to support the goal of remyeli-
nation as a means to prevent axon degeneration and
slow deficit progression in neurologic disease [14]. In
the year 2000, we reported the identification of a natural
human IgM that promoted robust spinal cord remyeli-
nation in both the TMEV-IDD and lysolecithin-induced
demyelination models [15, 16]. A recombinant form of
this human IgM, termed rHIgM22, was expressed in a
F3B6 cell line with the assembled IgM containing a
mouse J chain [17]. rHIgM22 binds to myelin and the
surface of oligodendrocytes (OL) and in pre-clinical
studies is effective in vivo at very low doses. A single
0.025 mg/kg intraperitoneal injection of rHIgM22 given
to TMEV-IDD mice with demyelination promoted sig-
nificant remyelination 5 weeks later [18] and increased
brainstem NAA concentrations [13], indicating a preser-
vation of axon health [19]. In a recently concluded dose
escalation clinical trial in humans with MS, rHIgM22
was tested at doses ranging from 0.025 up to 2 mg/kg
and found to be completely safe [20].
A second human IgM, rHIgM12, that promotes neur-
ite extension [4], improves brainstem NAA concentra-
tions without associated spinal cord remyelination,
suggesting that IgM-mediated neuroprotection can be
achieved by an alternate mechanism. In the current
study, we determined the minimum and optimum dose
of rHIgM12 to preserve spontaneous nocturnal function
in groups of TMEV-IDD mice. A dose of 0.25 mg/kg of
rHIgM12 improved only horizontal motor function,
whereas a dose of 2.5 mg/kg improved both horizontal
and vertical activities. An optimum dose of 10 mg/kg
provided the best improvement of both horizontal and
vertical nocturnal motor function and animals treated
with a higher dose of 25 mg/kg did not perform any bet-
ter. This study suggests that the single dose of rHIgM12
required for biological efficacy in mice is similar to the
dose of rHIgM22 required for remyelination. Following
identification of the optimum dose, we used the 10 mg/kg
dose of rHIgM12 to obtain direct evaluation of descending
axon integrity with retrograde labeling at the T6 level of
the spinal cord. Our previous work demonstrated that de-
myelination is normally accompanied by a reduction of
axonal transport [8, 21]. The majority of demyelinated le-
sions in TMEV-IDD occur at the cervical and thoracic
levels. Therefore, a reduction in the number of labeled
brainstem cells occurs primarily because of disturbed
retrograde transport or axonal degeneration. In this study,
treatment of SJL mice at 90 dpi with a single dose of
rHIgM12 protected the function of spinal cord axons;
resulting in 42 % more Fluoro-Gold-labeled brainstem
neurons (Fig. 3b) and 14.7 % more axons in the rHIgM12
group compared to the control IgM group. This suggests
that a preservation of less than 50 % of brainstem neurons
and axons was sufficient to observe functional effects, i.e.,
an improvement in spontaneous locomotor activity. Our
previous magnetic resonance spectroscopy study [7] and
neuron/axon-count analyses in the current study provide
strong evidence that the neurite outgrowth-promoting
antibody, rHIgM12, affected neuronal viability through
the preservation of axons. The concept that the degree of
axonal damage occurs independently of the extent of
chronic demyelination is supported by our data and sev-
eral other studies that examined gray matter lesions and
meningeal infiltrates in human brain and genetically ma-
nipulated mice [22–24].
The observed preservation of axons by rHIgM12 may
relate to the initially described neurite-promoting activity.
Studies of several classic neurotrophins link the promo-
tion of neurite outgrowth with neuroprotection [25, 26].
However, using these pleiotropic molecules in the clinic
has been problematic. Antibodies directed against the
myelin-derived protein Nogo-A promotes neurite out-
growth in the presence of normally inhibitory molecules
[27] and in vivo are therapeutic in models of ALS [28],
stroke [29], and spinal cord injury [30]. Treatment of rats
with Herceptin, a high-affinity IgG directed against the
extracellular domain of the human epidermal growth fac-
tor receptor 2 protein (HER2), enhanced axon regener-
ation after peripheral nerve injury [31]. rHIgM12 binds
with high affinity to gangliosides (GD1a and GT1b) [32]
and to polysialylated-neural cell adhesion molecule (PSA-
NCAM) [33]. GD1a and GT1b are also ligands for the
neurite inhibitory molecule myelin-associated glycopro-
tein (MAG) and facilitate interactions between OLs and
axons that maintain long-term axonal stability [34].
MAG-induced inhibition of axon extension involves the
rearrangement of neuronal membrane domains and re-
cruitment of p75 neurotrophin receptor to those domains
[35]. rHIgM12 binding to the neuronal surface also rear-
ranges plasma-membrane microdomains and clusters sig-
naling molecules, resulting in a shift of microtubule
stability and dynamics [36]. We hypothesize that
rHIgM12-mediated neurite outgrowth and protection
may use the same membrane platforms targeted by anti-
bodies to the neurite outgrowth inhibitor A (Nogo-A) and
the leucine rich repeat and immunoglobulin-like domain-
containing protein 1 (LINGO-1) [37, 38]. Given that
rHIgM12 is produced as a fully human antibody, we ex-
pect no toxicity even at higher doses in human studies.
Among these neuroprotective reagents, only rHIgM12 was
isolated from a human. Most antibody-based therapeutics
are humanized forms of originally non-human antibodies.
Even humanized antibodies can provoke the synthesis of
anti-therapeutic antibodies such as those observed against
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an anti-CD25 [39] that may limit their long-term effective-
ness in humans. Herceptin, used to treat certain breast can-
cers, carries FDA warnings for cardiomyopathy and
embryo-fetal toxicity that limit its widespread use.
Small molecule-based neuroprotective strategies include
anti-excitotoxic agents [40, 41], nitric oxide and iNOS in-
hibitors [42], anti-oxidants [43], Ca2+ channel blockers
[44], Na+ channel blockers [45], Na+/Ca2+ exchanger inhib-
itors and growth/neurotrophic factors [46, 47], neural pep-
tides [48], and components of essential oils [49]. A recent
study of the MS drug FTY720 reports that this small mol-
ecule induces neurite growth, alters growth cone morph-
ology, and promotes axon regeneration [50]. FTY720
treatment of cerebellar neurons induced components of
the actin cytoskeleton, which are important for axon
growth, but did not alter the levels of tubulin tyrosination
or acetylation. In contrast, treatment of cortical neurons
with rHIgM12 increased the level of tyrosinated tubulin
while decreasing the levels of acetylated tubulin, consistent
with promoting a more dynamic cytoskeleton needed for
axon growth.
In conclusion, our results provide direct evidence for
human antibody-mediated protection of axon integrity
in a mouse model of progressive MS. To our best know-
ledge, rHIgM12 is the first human IgM antibody that is
neuroprotective in the absence of remyelination. Com-
bined treatment using both rHIgM22 and rHIgM12 may
result in enhanced neuroprotection and better remyeli-
nation. However, in TMEV-IDD, complete repair is likely
not possible due to the persistent presence of virus. In
fact, some of the best histologic repair in TMEV-IDD is
driven by treatment with polyclonal human IgM [15],
which contains antibodies that bind to both OLs and
neurons. A cocktail of human IgMs may be functionally
equivalent to this limited resource.
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